A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies

Purpose Veliparib (V), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, potentiates effects of alkylating agents and topoisomerase inhibitors in preclinical tumor models. We conducted a phase I trial of V with iv cyclophosphamide (C) and V plus iv doxorubicin (A) and C. Methods Objectives were...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology 2022-01, Vol.89 (1), p.49-58
Hauptverfasser:	Tan, Antoinette R., Chan, Nancy, Kiesel, Brian F., Stein, Mark N., Moss, Rebecca A., Malhotra, Jyoti, Aisner, Joseph, Shah, Mansi, Gounder, Murugesan, Lin, Hongxia, Kane, Michael P., Lin, Yong, Ji, Jiuping, Chen, Alice, Beumer, Jan H., Mehnert, Janice M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Alkylating agents Alkylation Anemia Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Benzimidazoles - administration & dosage Benzimidazoles - pharmacokinetics Blood circulation Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Cancer Research Cancer therapies Chemotherapy Cyclophosphamide Cyclophosphamide - administration & dosage Cyclophosphamide - blood Cyclophosphamide - pharmacokinetics DNA damage DNA repair Doxorubicin Doxorubicin - administration & dosage Evaluation Female Humans Leukocytes (mononuclear) Male Maximum Tolerated Dose Medicine Medicine & Public Health Metastases Metastasis Middle Aged Neoplasms - drug therapy Neoplasms - pathology Neutropenia Oncology Original Article Patients Peripheral blood mononuclear cells Pharmacokinetics Pharmacology Pharmacology/Toxicology Poly Adenosine Diphosphate Ribose - blood Poly(ADP-ribose) Poly(ADP-ribose) polymerase Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage Poly(ADP-ribose) Polymerase Inhibitors - pharmacokinetics Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Ribose Schedules Tumor cells Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!